{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:35:15Z","timestamp":1793230515514,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1016\/j.amjmed.2004.03.040","type":"journal-article","created":{"date-parts":[[2004,9,30]],"date-time":"2004-09-30T11:17:26Z","timestamp":1096543046000},"page":"508-515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Adverse effects of thalidomide administration in patients with neoplastic diseases"],"prefix":"10.1016","volume":"117","author":[{"given":"Meletios A.","family":"Dimopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vagelis","family":"Eleutherakis-Papaiakovou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2004.03.040_bib1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor-a production by stimulated human monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.amjmed.2004.03.040_bib2","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.amjmed.2004.03.040_bib3","doi-asserted-by":"crossref","first-page":"22382","DOI":"10.1074\/jbc.M100938200","article-title":"Inhibitor of NF-Kappa B activity by thalidomide through suppression of I Kappa B kinase activity","volume":"276","author":"Keifer","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.amjmed.2004.03.040_bib4","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1084\/jem.187.11.1885","article-title":"Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset","volume":"187","author":"Haslett","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.amjmed.2004.03.040_bib5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0162-3109(95)00050-X","article-title":"Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade","volume":"31","author":"Geitz","year":"1996","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.amjmed.2004.03.040_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0037-1963(00)90077-5","article-title":"Pharmacology of thalidomide","volume":"37","author":"Stirling","year":"2000","journal-title":"Semin Hematol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib7","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1211\/0022357001774660","article-title":"Intravenous formulations of the enantiomers of thalidomide: pharmacokinetics and initial pharmacodynamic characterization in man","volume":"52","author":"Eriksson","year":"2000","journal-title":"J Pharmacol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1021\/js980172i","article-title":"Pharmacokinetics of thalidomide in an elderly prostate cancer population","volume":"88","author":"Figg","year":"1999","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.amjmed.2004.03.040_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/00002018-200124020-00002","article-title":"Thalomid\u00ae (Thalidomide) capsules. A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing","volume":"24","author":"Clark","year":"2001","journal-title":"Drug Safety"},{"key":"10.1016\/j.amjmed.2004.03.040_bib10","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/(SICI)1099-0461(2000)14:3<140::AID-JBT3>3.0.CO;2-P","article-title":"Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients","volume":"14","author":"Teo","year":"2000","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib11","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0006-2952(98)00046-X","article-title":"Inhibition of angiogenesis requires metabolic activation, which is species-dependent","volume":"55","author":"Bauer","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib12","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1182\/blood-2002-03-0939","article-title":"Antimyeloma efficacy of thalidomide in the SCID-hu model","volume":"100","author":"Yaccoby","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2004.03.040_bib13","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4161\/cbt.318","article-title":"Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide","volume":"1","author":"Ando","year":"2002","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.amjmed.2004.03.040_bib14","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2004.03.040_bib15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2004.03.040_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1182\/blood-2002-09-2846","article-title":"A multicentre phase II trial of thalidomide in relapsed\/refractory multiple myeloma: adverse prognostic impact of advanced age","volume":"102","author":"Mileshkin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2004.03.040_bib17","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood.V98.4.958","article-title":"Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes","volume":"98","author":"Raza","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2004.03.040_bib18","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1200\/JCO.2001.19.16.3596","article-title":"Treatment of Waldenstrom's macroglobulinemia with thalidomide","volume":"19","author":"Dimopoulos","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib19","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood.V99.3.834","article-title":"Efficacy and safety of thalidomide in patients with acute myeloid leukemia","volume":"99","author":"Steins","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2004.03.040_bib20","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1365-2141.2003.04639.x","article-title":"Single agent thalidomide in patients with relapsed or refractory acute myeloid leukemia","volume":"123","author":"Thomas","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib21","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1080\/1042819021000040008","article-title":"Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies","volume":"43","author":"Barosi","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.amjmed.2004.03.040_bib22","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1200\/JCO.2000.18.13.2593","article-title":"Activity of thalidomide in AIDS-related Kaposi's sarcoma","volume":"18","author":"Little","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib23","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1054\/bjoc.2001.2025","article-title":"The treatment of advanced renal cell cancer with high dose oral thalidomide","volume":"85","author":"Stebbing","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.amjmed.2004.03.040_bib24","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/annonc\/mdf213","article-title":"Phase II trial of thalidomide in renal cell carcinoma","volume":"13","author":"Escudier","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib25","first-page":"1888","article-title":"A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer","volume":"7","author":"Figg","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"suppl 15","key":"10.1016\/j.amjmed.2004.03.040_bib26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0093-7754(01)90157-5","article-title":"A randomized phase II trial of docetaxel (Taxotere) plus thalidomide in androgen-independent prostate cancer","volume":"28","author":"Figg","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib27","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1200\/JCO.2000.18.4.708","article-title":"Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas","volume":"18","author":"Fine","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib28","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1054\/bjoc.1999.1004","article-title":"Continuous low dose thalidomide; a phase II study in advanced melanoma, renal cancer, ovarian and breast cancer","volume":"82","author":"Eisen","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.amjmed.2004.03.040_bib29","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1200\/JCO.2000.18.14.2710","article-title":"Phase II evaluation of thalidomide in patients with metastatic breast cancer","volume":"18","author":"Baidas","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib30","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/sj.bmt.1701138","article-title":"The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children","volume":"21","author":"Rovelli","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.amjmed.2004.03.040_bib31","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1023\/A:1008329821941","article-title":"Thalidomide in patients with cachexia due to terminal cancer: preliminary report","volume":"10","author":"Bruera","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib32","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0006-2952(99)00388-3","article-title":"Mechanism of action in thalidomide teratogenesis","volume":"59","author":"Stephens","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib33","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0095-5108(18)30810-8","article-title":"The thalidomide syndrome: risks of exposure and spectrum of malformations","volume":"13","author":"Newman","year":"1986","journal-title":"Clin Perinatol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/1520-6866(2000)20:5<301::AID-TCM6>3.0.CO;2-2","article-title":"Assessment of the in vitro and in vivo genotoxicity of thalomid\u00ae (Thalidomide)","volume":"20","author":"Teo","year":"2000","journal-title":"Teratog Carcinog Mutagen"},{"key":"10.1016\/j.amjmed.2004.03.040_bib35","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2165\/00002018-199819050-00001","article-title":"Does thalidomide cause second generation birth defects","volume":"19","author":"Smithells","year":"1998","journal-title":"Drug Safety"},{"key":"10.1016\/j.amjmed.2004.03.040_bib36","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0149-2918(00)88289-2","article-title":"S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide","volume":"21","author":"Zieldis","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjmed.2004.03.040_bib37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/01.WNL.0000043691.53710.53","article-title":"Toxic neuropathy in patients with pre-existing neuropathy","volume":"60","author":"Chaudhry","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.amjmed.2004.03.040_bib38","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archderm.1994.01690010070009","article-title":"Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients","volume":"130","author":"Ochonisky","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib39","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1523-1747.2002.19502.x","article-title":"Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients","volume":"119","author":"Bastuji-Garin","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF00313852","article-title":"Thalidomide-induced peripheral neuropathy: a prospective clinical, neurophysiological and pharmacogenetic evaluation","volume":"223","author":"Hess","year":"1986","journal-title":"J Neurol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib41","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/jnnp.31.6.543","article-title":"Thalidomide neuropathy: a clinical, electrophysiological, and histological follow-up study","volume":"31","author":"Fullerton","year":"1968","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.amjmed.2004.03.040_bib42","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1212\/01.WNL.0000049462.03800.B1","article-title":"Thalidomide-induced neuropathy: a gangliopathy","volume":"60","author":"Giannini","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.amjmed.2004.03.040_bib43","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/1097-4598(200008)23:8<1301::AID-MUS25>3.0.CO;2-4","article-title":"Thalidomide neuropathy: role of F-wave monitoring","volume":"23","author":"Walter","year":"2000","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.amjmed.2004.03.040_bib44","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/mus.1109","article-title":"Thalidomide neuropathy in patients treated for metastatic prostate cancer","volume":"24","author":"Molloy","year":"2001","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.amjmed.2004.03.040_bib45","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2133.1985.tb02323.x","article-title":"Development of polyneuropathy during thalidomide therapy","volume":"112","author":"Wulff","year":"1985","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib46","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1079-2104(97)90032-9","article-title":"Thalidomide-induced perioral neuropathy","volume":"84","author":"Elad","year":"1997","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.amjmed.2004.03.040_bib47","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1212\/01.WNL.0000037480.59194.85","article-title":"Thalidomide-induced neuropathy","volume":"59","author":"Chaudhry","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.amjmed.2004.03.040_bib48","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0093-7754(01)90030-2","article-title":"Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions","volume":"28","author":"Desikan","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib49","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0753-3322(01)00146-9","article-title":"Thalidomide in cancer","volume":"56","author":"Singhal","year":"2002","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.amjmed.2004.03.040_bib50","first-page":"111","article-title":"Pharmacological properties of thalidomide (a-phthalimido glutarimide), a new sedative hypnotic drug","volume":"15","author":"Somers","year":"1960","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib51","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1056\/NEJM200305013481822","article-title":"Reversible dementia due to thalidomide therapy for multiple myeloma","volume":"348","author":"Morgan","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2004.03.040_bib52","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2002.20.5.1429","article-title":"Unexpected toxicity of combination thalidomide and interferon alfa-2a treatment in metastatic renal cell carcinoma","volume":"20","author":"Nathan","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib53","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0002-9343(02)01300-1","article-title":"Thalidomide-associated deep vein thrombosis and pulmonary embolism","volume":"113","author":"Bennet","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2004.03.040_bib54","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1182\/blood-2002-06-1674","article-title":"Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy [correspondence]","volume":"100","author":"Cavo","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2004.03.040_bib55","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJM200106213442516","article-title":"Deep venous thrombosis and thalidomide therapy for multiple myeloma","volume":"344","author":"Osman","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2004.03.040_bib56","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/cncr.10847","article-title":"A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma","volume":"95","author":"Desai","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.amjmed.2004.03.040_bib57","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood-2002-01-0335","article-title":"Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy","volume":"100","author":"Zangari","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2004.03.040_bib58","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib59","first-page":"389","article-title":"Abrogation of thrombogenic effect of the doxorubicin-thalidomide combination as part of total therapy II for newly diagnosed multiple myeloma by effective anticoagulation with low molecular weight heparin","volume":"100","author":"Zangari","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2004.03.040_bib60","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1345\/aph.1D003","article-title":"Thalidomide-induced sinus bradycardia","volume":"37","author":"Kaur","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.amjmed.2004.03.040_bib61","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0753-3322(02)00177-4","article-title":"Thalidomide, an antiangiogenic agent with clinical activity in cancer","volume":"56","author":"Ng","year":"2002","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.amjmed.2004.03.040_bib62","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1086\/513665","article-title":"Adverse reactions to thalidomide in patients infected with human immunodeficiency virus","volume":"24","author":"Haslett","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2004.03.040_bib63","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1093\/annonc\/mdf258","article-title":"The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma","volume":"13","author":"Grover","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib64","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1592\/phco.19.15.1177.30571","article-title":"Thalidomide-induced toxic epidermic necrolysis","volume":"19","author":"Horowitz","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.amjmed.2004.03.040_bib65","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000246827","article-title":"Erythroderma due to thalidomide: report of two cases","volume":"189","author":"Biesla","year":"1994","journal-title":"Dermatology"},{"key":"10.1016\/j.amjmed.2004.03.040_bib66","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1056\/NEJM200009283431315","article-title":"Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma","volume":"343","author":"Rajkumar","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2004.03.040_bib67","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1067\/mjd.2003.87","article-title":"Dermatologic side effects of thalidomide in patients with multiple myeloma","volume":"48","author":"Hall","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib68","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/bmj.1.5062.84","article-title":"Antithyroid activity of N-phthaloyl glutamic acid","volume":"1","author":"Murdoch","year":"1958","journal-title":"BMJ"},{"key":"10.1016\/j.amjmed.2004.03.040_bib69","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0002-9343(01)01137-8","article-title":"Hypothyroidism in patients with multiple myeloma following treatment with thalidomide","volume":"112","author":"Badros","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2004.03.040_bib70","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00001721-200204000-00003","article-title":"Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications","volume":"13","author":"Zangari","year":"2002","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.amjmed.2004.03.040_bib71","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2141.2003.04252.x","article-title":"Thromboembolic events in patients with myelodysplastic syndromes receiving thalidomide in combination with darbepoietin-alpha","volume":"121","author":"Steurer","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib72","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1365-2141.2001.03095.x","article-title":"Thrombogenic role of cells undergoing apoptosis","volume":"115","author":"Wang","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib73","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.2002.20.13.3042","article-title":"Endothelial dysfunction antiangiogenesis-associated thrombosis","volume":"20","author":"Kaushal","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib74","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1128\/JCM.40.6.2302-2304.2002","article-title":"Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma","volume":"40","author":"Curley","year":"2002","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib75","first-page":"ELT12","article-title":"Fatal sepsis after thalidomide\/dexamethasone treatment in two patients with multiple myeloma","volume":"88","author":"Wolfler","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.amjmed.2004.03.040_bib76","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1182\/blood.V96.12.4007","article-title":"Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia","volume":"96","author":"Tefferi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2004.03.040_bib77","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00045391-200305000-00011","article-title":"Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide","volume":"10","author":"Behrens","year":"2003","journal-title":"Am J Ther"},{"key":"10.1016\/j.amjmed.2004.03.040_bib78","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1365-2141.2003.04245_2.x","article-title":"Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma [correspondence]","volume":"121","author":"Younis","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib79","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.2337\/diacare.26.4.1322-a","article-title":"Thalidomide-associated hyperglycemia and diabetes","volume":"26","author":"Pathak","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2004.03.040_bib80","first-page":"1112","article-title":"Thalidomide and sexual dysfunction in men","volume":"146","author":"Pouaha","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib81","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1046\/j.1365-2133.2001.04268.x","article-title":"Thalidomide-induced amenorrhoea; two cases","volume":"144","author":"Passeron","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib82","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/0306-3623(95)00019-W","article-title":"Exacerbation of acetaminophen hepatotoxicity by thalidomide and protection by nicotinic acid amide","volume":"26","author":"Kroger","year":"1995","journal-title":"Gen Pharmacol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib83","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/ajh.1062","article-title":"Thalidomide-associated hepatitis: a case report","volume":"66","author":"Fowler","year":"2001","journal-title":"Am J Hematol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib84","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/annonc\/mdg095","article-title":"Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma","volume":"14","author":"Trojan","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib85","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1365-2141.2003.04395_2.x","article-title":"Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia","volume":"122","author":"Harris","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib86","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.1365-2141.2002.03835_4.x","article-title":"Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions","volume":"119","author":"Jones","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib87","first-page":"383B","article-title":"No evidence for an adverse interaction between zoledronic acid and thalidomide: preliminary safety analysis from the Australasian Leukemia and Lymphoma Group MM6 Myeloma Trial","volume":"102","author":"Spencer","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2004.03.040_bib88","first-page":"2212","article-title":"Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma","volume":"20","author":"Cany","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib89","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-\u03b1","volume":"163","author":"Corral","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.amjmed.2004.03.040_bib90","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2004.03.040_bib91","first-page":"236","article-title":"An update of the use and outcomes of the new immunomodulatory agent CC-4047 (Actimid) in patients with relapse\/refractory myeloma","volume":"102","author":"Streetly","year":"2003","journal-title":"Blood"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934304004309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934304004309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:30:50Z","timestamp":1757579450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934304004309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":91,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["S0002934304004309"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2004.03.040","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2004,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse effects of thalidomide administration in patients with neoplastic diseases","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2004.03.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}